Dr Duncan F Rogers

External collaborations

GlaxoSmithKline (UK), Dr Keith Bunce.

GlaxoSmithKline (USA), Dr Thomas Leonard.

Health Protection Agency (Porton Down), Dr Keith Foster.

GlaxoSmithKline (UK), Dr Malcolm Johnson.

GlaxoSmithKline (USA), Dr Rupert Vessey.

External committees

Scientific Committee, British Lung Foundation. Member. 2000 - 2003.

Public Relations Board, Institute of Biology. Member. 2001 - 2003.

Fellowships

Institute of Biology, Fellow.

Guest lectures

2002 International Meeting of the Interest Group for Cilia, Mucus and Mucociliary Interactions, 'Airway mucus hypersecretion and considerations for rational novel therapy.'. Miami Beach, USA. 2002.

COPD 3, International Convention Centre. 'Mucus regulation.'. Birmingham, UK. 2002.

National Clinical Coding Conference. 'Mucous hypersecrtetion in asthma and COPD.'. London, UK. 2002.

British Society for Allergy & Clinical Immunology: 'Neuronal Control of airway mucus secretion'. East Midlands Conference Centre, Nottingham, UK. 2003.

British Association for Lung Research: 'Regulation of airway mucin secretion: stimulation and inhibition in expermental models and human disease'. University of Brighton, UK. 2003.

6th Annual Conference on COPD: 'Mucus hypersecretion in COPD: pathophysiology and novel treatments'. Management Forum, London, UK. 2003.

COPD: The Important Questions III: 'Mucoregulators'. Marbella, Spain. 2004.

The Breathing Club: All Change in COPD: ' Mucus regulation and treatment'. Chantilly, France. 2004.

'Airway mucosa: secretory cells, mucus and mucin genes'. The XXth Congress of the European Acadamy of Allergology and Clinical Immunology, Berlin, Germany. 2001.

'Mucus hypersecretion in asthma and COPD: pathophysiology and models'. Roche Bioscience, Palo Alto, USA. 2001.

'Mucin gene expression in airway inflammation'. The Rayne Institute, University College London. 2001.

Airway mucin gene expression: pathophysiology and models'. Department of Cell and Molecular Biology, University of Lund, Sweden. 2001.

'Mucus hypersecretion in asthma and COPD: pathophysiology, models and treatment'. Merck Frosst Canada, Quebec, Canada. 2002.

'Airway mucus hypersecretion: models and therapies'. AstraZeneca, Charnwood, Loughborough. 2003.

'Airway secretions'. The Triangle of Asthma Management, Imperial College London. 2003.

'Airway mucus hypersecretion: basic mechanisms and novel pharmacotherapy'. Molecular Biology of the Cell Forum, University of Sunderland. 2003.

'Airway mucus secretion: stimulation and rational approaches to inhibition of hypersecretion'. Centre for Applied Microbiological Research, Porton Down, Salisbury. 2003.

'Airway mucus hypersecretion: models and pharmacotherapies'. Oxagen Limited, Oxford. 2004.

'Mucus regulation and treatment in asthma, COPD and allergic rhinitis'. Asthma and Allergy Research group, NHLI, Imperial College London. 2004.

'Airway mucus hypersecretion: new pharmacotherapy in asthma and COPD'. The Rayne Institute, University College London. 2004.

'Mucus hypersecretion and modyfying agents'. Annual Conference on COPD, Management Forum, London. 2004.

'Airway mucus hypersecretio: basic mechanisms and rationales for novel therapy'. Heatherwood and Wexham NHS Trust Medical half Day, Heatherwood Hospital, Ascot. 2004.

'Targeting mucus production in lung disease'. British Thoracic Society Winter Meeting, London. 2004.

Editorial boards

Current Drugs, Member, Panel of Evaluators. 1998 - 2003.

Experimental Lung Research, Editor-in-Chief. 2001 -

Thorax, Member, Advisory Board. 1997 - 2003.